Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12104/64866
Full metadata record
DC FieldValueLanguage
dc.contributor.authorArmendariz-Borunda, J.
dc.contributor.authorRincon, A.R.
dc.contributor.authorMunoz-Valle, J.F.
dc.contributor.authorBueno-Topete, M.
dc.contributor.authorOregon-Romero, E.
dc.contributor.authorIslas-Carbajal, M.C.
dc.contributor.authorMedina-Preciado, D.
dc.contributor.authorGonzalez-Garcia, I.
dc.contributor.authorBautista, A.
dc.contributor.authorGarcia-Rocha, S.
dc.contributor.authorGodoy, J.
dc.contributor.authorMercado, M.V.-D.
dc.contributor.authorTroyo-SanRoman, R.
dc.contributor.authorArellano-Olivera, I.
dc.contributor.authorLucano, S.
dc.contributor.authorAlvarez-Rodriguez, A.
dc.contributor.authorSalazar, A.
dc.date.accessioned2015-11-19T18:49:49Z-
dc.date.available2015-11-19T18:49:49Z-
dc.date.issued2008
dc.identifier.urihttp://hdl.handle.net/20.500.12104/64866-
dc.description.abstractBackground/Aim: The aim of this work was to establish a potential correlation between specific polymorphisms and presence of hepatic fibrosis in Mexican patients with established liver fibrosis (ELF). Second, necroinflammatory index improvement was correlated with Pirfenidone (PFD) treatment response and the same polymorphisms. Methods: We analyzed TGF-β polymorphisms in codon 25, a single basepair guanine insertion-deletion polymorphism (4G/5G) for PAI-1 and angiotensin AT-6 single nucleotide polymorphism located in -6 promoter region. Twenty patients infected with either hepatitis C virus (HCV) (n = 13) or affected by alcohol consumption (n = 7) were included. Thirty subjects with no hepatic damage were included in control group. Blood samples for genomic DNA were obtained and plasminogen activator inhibitor-1 polymorphisms were done by polymerase chain reaction-artificial introduction of a restriction site, TGF-β by polymerase chain reaction-amplification refractory mutation system and AT by polymerase chain reaction-restriction fragment length polymorphisms. Liver biopsies were obtained at baseline and after 12 months of PFD treatment. Results: Established liver fibrosis patients had the homo-zygote G/G TGF-β genotype, which has been associated with increased development of fibrosis. None of our patients had the G/C genotype. All pure HCV and pure alcohol abuse subjects carried G/G TGF-β genotype (100% vs 37% control) (P = 0.0006). The odds of having β G/G genotype was 19.5 for HCV patients and 10.83 for alcohol consumption patients as compared with healthy subjects (P < 0.001). Established liver fibrosis patients had an improvement in necroinflammatory index after PFD treatment when correlated with plasminogen activator inhibitor-1 and angiotensinogen-6 genotypes. Conclusion: Our data suggested that a combination of inherited polymorphisms increased the risk of advanced fibrosis in ELF patients. Pure HCV and pure alcohol consumption patients which were homozygous G/G carriers had 19.5- and 10.8-fold higher risk to develop advanced fibrosis respectively. © 2008 by The American Federation for Medical Research.
dc.titleFibrogenic polymorphisms (TGF-β, PAI-1, AT) in Mexican patients with established liver fibrosis. Potential correlation with pirfenidone treatment
dc.typeArticle
dc.relation.ispartofjournalJournal of Investigative Medicine
dc.relation.ispartofvolume56
dc.relation.ispartofissue7
dc.relation.ispartofpage944
dc.relation.ispartofpage953
dc.subject.keywordAT; Cirrhosis; PAI-1; Pirfenidone; Polymorphisms; TGF-β
dc.contributor.affiliationArmendáriz-Borunda, J., Institute of Molecular Biology in Medicine and Gene Therapy, CUCS, University of Guadalajara, P.O. Box 2-123, Guadalajara, Jalisco, 44281, Mexico, OPD Civil Hospital, Juan I Menchaca, Mexico; Rincón, A.R., Institute of Molecular Biology in Medicine and Gene Therapy, CUCS, University of Guadalajara, P.O. Box 2-123, Guadalajara, Jalisco, 44281, Mexico, Institute of Chronic and Degenerative Diseases, CUCS, University of Guadalajara, Mexico; Muñoz-Valle, J.F., Institute of Rheumatology Research and Muscle Skeletal System, CUCS, University of Guadalajara, Mexico; Bueno-Topete, M., Institute of Molecular Biology in Medicine and Gene Therapy, CUCS, University of Guadalajara, P.O. Box 2-123, Guadalajara, Jalisco, 44281, Mexico; Oregón-Romero, E., Institute of Rheumatology Research and Muscle Skeletal System, CUCS, University of Guadalajara, Mexico; Islas-Carbajal, M.C., Institute of Molecular Biology in Medicine and Gene Therapy, CUCS, University of Guadalajara, P.O. Box 2-123, Guadalajara, Jalisco, 44281, Mexico; Medina-Preciado, D., OPD Civil Hospital, Juan I Menchaca, Mexico; González-Garćia, I., OPD Civil Hospital, Juan I Menchaca, Mexico; Bautista, A., OPD Civil Hospital, Juan I Menchaca, Mexico; Garćia-Rocha, S., OPD Civil Hospital, Juan I Menchaca, Mexico; Godoy, J., OPD Civil Hospital, Juan I Menchaca, Mexico; Mercado, M.V.-D., Institute of Rheumatology Research and Muscle Skeletal System, CUCS, University of Guadalajara, Mexico; Troyo-SanRoman, R., Physiology Department CUCS, University of Guadalajara, Mexico; Arellano-Olivera, I., Institute of Molecular Biology in Medicine and Gene Therapy, CUCS, University of Guadalajara, P.O. Box 2-123, Guadalajara, Jalisco, 44281, Mexico, Zone General Hospital No. 9, IMSS, Jalisco, Mexico; Lucano, S., Institute of Molecular Biology in Medicine and Gene Therapy, CUCS, University of Guadalajara, P.O. Box 2-123, Guadalajara, Jalisco, 44281, Mexico; Álvarez-Rodŕiguez, A., Institute of Molecular Biology in Medicine and Gene Therapy, CUCS, University of Guadalajara, P.O. Box 2-123, Guadalajara, Jalisco, 44281, Mexico; Salazar, A., Institute of Molecular Biology in Medicine and Gene Therapy, CUCS, University of Guadalajara, P.O. Box 2-123, Guadalajara, Jalisco, 44281, Mexico
dc.subject.headingIndex Medicus;Adult;Aged;Angiotensinogen/ge [Genetics];Anti-Inflammatory Agents, Non-Steroidal/tu [Therapeutic Use];Base Sequence;DNA Primers/ge [Genetics];Female;Hepatitis C/dt [Drug Therapy];Hepatitis C/ge [Genetics];Humans;Liver Cirrhosis/dt [Drug Therapy];Liver Cirrhosis/ge [Genetics];Liver Cirrhosis, Alcoholic/dt [Drug Therapy];Liver Cirrhosis, Alcoholic/ge [Genetics];Male;Mexico;Middle Aged;Plasminogen Activator Inhibitor 1/ge [Genetics];Polymorphism, Genetic;Pyridones/tu [Therapeutic Use];Transforming Growth Factor beta/ge [Genetics]
dc.relation.isReferencedByScopus
dc.relation.isReferencedByMEDLINE
dc.relation.isReferencedByWOS
dc.identifier.urlhttp://www.scopus.com/inward/record.url?eid=2-s2.0-58149171859&partnerID=40&md5=2d9bdf46f3633f1bdbec471aff3ce078
dc.identifier.urlhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18797412
Appears in Collections:Producción científica UdeG (prueba)

Files in This Item:
There are no files associated with this item.


Items in RIUdeG are protected by copyright, with all rights reserved, unless otherwise indicated.